Core Insights - ANI Pharmaceuticals Inc is focused on becoming a leader in the rare disease sector while also developing and marketing both branded and generic prescription pharmaceuticals [1][5] - The company has set ambitious sales targets for 2026, aiming for over $1 billion in sales [2][5] Financial Performance - In 2025, ANI reported revenues of $883 million, representing a 44% increase from the previous year [3][5] - The adjusted non-GAAP EBITDA for 2025 was $230 million, marking a 47% year-over-year growth [3][5] Market Position - ANI expects its rare disease segment to contribute approximately 60% of total revenues by 2026 [3] - The current stock price of ANIP is $75.60, with a market capitalization of approximately $1.70 billion [4]